A clinical trial involving 25 healthy volunteers found that an experimental chikungunya vaccine developed by U.S. government researchers triggered a strong immune response against the mosquito-borne viral disease. Different doses were tested over the course of three injections, and antibodies to chikungunya were still present at least 11 months after the last dose, according to findings reported in The Lancet.

Related Summaries